Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the univariate analysis, studies were separated by the study design, the number of metastatic sites, the site of metastases, radiotherapy machine, and prostate-specific antigen level at the time of SBRT.
|
31809327 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In the multivariate analysis, the Gleason score, PSA and presence of metastases were associated with shorter OS and PFS.
|
29891440 |
2020 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The study confirmed that patients with high PSA level and fast PSA increase are likely to be diagnosed with both, local relapse and metastases.
|
31568268 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The correlation between PSA value and presence of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging.
|
30900618 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
It found that PSA-based screening in men aged 55 to 69 years prevents approximately 1.3 deaths from prostate cancer over 13 years per 1000 men screened and 3 cases of metastatic cancer per 1000 men screened, with no reduction in all-cause mortality.
|
31158876 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A significant (p ≤ 0.05) correlation between SUV<sub>max</sub> in PSMA-positive liver metastases and both size (ρ<sub>Spearman</sub> = 0.57) of metastases and PSA serum level (ρ<sub>Spearman</sub> = 0.60) was found.
|
31186052 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA ≥ 5.5 ng/mL, locoregional nodal involvement determined by pathology (pN1), prior primary radiation, and prior salvage radiotherapy independently predicted M1 disease (all <i>P</i> < 0.05).
|
31511295 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Median PSA level was 142ng/ml and 67% of patients had more than five osseous metastases.Median follow up was 47 mo.
|
30266309 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In univariate analyses, post-neoAS, pre-RT PSA level >0.1 ng/mL was associated with increased risks of biochemical failure (hazard ratio [HR], 2.04; P < .0001); local failure (HR, 2.51; P < .0001); distant metastases (HR, 1.73; P = .0006); cause-specific mortality (HR, 2.36; P < .0001); and all-cause mortality (HR, 1.24; P = .005).
|
30959123 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These patients were subdivided by PSA level (0-9.9, 10.0-19.9, 20.0-39.9, 40.0-59.9, 60.0-79.9, 80.0-97.9, and ≥98.0 ng/mL), nodal status (N0 vs N1), and distant metastases (M0 vs M1).
|
31390585 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases.
|
31325132 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Although our observational study design cannot pinpoint the exact cause of this increase, which is likely multifactorial, this shift reverses declines in metastases at diagnoses that followed the advent of prostate-specific antigen screening.
|
31522862 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the percentage of patients with GS ≥ 8 or metastases increased as PSA levels increased up to approximately 70 ng / mL, there was no significant increase between 70 and 100 ng / mL.
|
30521173 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although it is generally accepted that higher PSA values indicate higher disease burden, few data are available on the relation between PSA levels and number of detected metastases on PSMA PET/CT.
|
31274553 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases).
|
30576268 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Data of age, clinical stage, Gleason grade(GG), previous treatments, site of metastases, Prostate-specific antigen (PSA) values, TTCR, overall survival, biochemical progression free survival(PFS) and PSA response to docetaxel were recorded.
|
30636274 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant differences in AUCs for IL-35 and prostate-specific antigen were observed with regard to the presence of lymph node and distant metastases in patients with PCA.
|
31186721 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded.
|
30006752 |
2018 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
[68Ga]PSMA-11, which is the most frequently applied tracer, has shown to detect lymph node metastases, local recurrences, distant metastases and intraprostatic foci with high sensitivity, even at relatively low PSA levels.
|
29869483 |
2018 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CONCLUSIONS The urinary sarcosine/creatinine ratio was a diagnostic indicator of prostate cancer, for patients with a serum PSA level <10 ng/ml, and correlated with the Gleason score and with the presence of metastases (stage) of prostate cancer.
|
29741162 |
2018 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Particularly in patients with PSA levels above 1.0 ng/mL, a <sup>68</sup>Ga-PSMA ligand PET/CT should be performed for therapy planning, since patients often have metastases not confined to the pelvis.
|
29134231 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Univariable Cox regression determined pathological Gleason grade (P = 0.021), seminal vesicle invasion (P = 0.010), and first postoperative PSA ≥0.2 ng/ml (P = 0.005) were associated with metastases.
|
29429895 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In stage D0, the Prostate-Specific Antigen (PSA) slope is prognostic of time to radiographic evidence of metastases and death.
|
29143114 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Those with an early prostate specific antigen doubling time of 3 to 8.9 months were at increased risk for castration resistant prostate cancer (HR 3.56, p = 0.015), all cause mortality (HR 1.67, p = 0.006) and prostate cancer specific mortality (HR 3.17, p = 0.044) but not metastases (p = 0.13).
|
28870860 |
2018 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The number of sites (prostate bed, lymph nodes, distant metastases) with positive PSMA uptake was significantly associated with PSA values before imaging (P = 0.0032).
|
29777523 |
2018 |